Patients with unrecognized bipolar disorders (UBP) are often treated for depression prior to being correctly diagnosed, thus delaying appropriate drug therapy. This study compared hospital use, attempted suicides and one-year post-treatment costs of UBP patients relative to patients with major depressive disorders (MDD) and recognized bipolar (RBP) patients. METHODS: Data from the California Medicaid program for the period October 1994 to January 1999 were used to identify 25,308 adult patients who initiated a new episode of antidepressant therapy. RBP patients received their initial diagnosis of bipolar disorders or used mood stabilizers on or before the initiation of antidepressant therapy. UBP patients initiated antidepressant therapy with an initial MDD diagnosis, then received a bipolar disorder diagnosis or initiated mood stabilizer therapy at a later date. Multivariate models were used to estimate the marginal risks and costs associated with UBP patients relative to RBP or MDD-only patients. RESULTS: RBP and UBP patients represented 15.4% and 6.3% of all antidepressant users, respectively. UBP patients had higher rates of hospital use (12.5%) and attempted suicide (0.88%) than RBP patients (11.2% and 0.29%) or MDD patients (7.5% and 0.18%). Multivariate results indicated that UBP patients were three times more likely to use hospital services (p < 0.0001) and 3.2 times more likely to attempt suicide (p = 0.0004) than MDD patients. RBP patients were twice as likely to use hospital care (p < 0.0001) than MDD patients. UBP was associated with higher 1-year outpatient costs relative to RBP patients (+$200; p < 0.05), but was not associated with higher inpatient or total costs. RBP was associated with lower one-year outpatient costs ($109; p < 0.05) but higher inpatient costs ($634; p < 0.001) and total costs ($508; p < 0.01) relative to MDD patients. CONCLUSIONS: UBP is both common and costly. More effort is needed to provide early and correct diagnosis, and to effectively treat these patients. 
OBJECTIVE:
This study compared treatment patterns and costs for bipolar disorder (BP) patients (recognized and unrecognized) to those of major depression disorder (MDD) patients without a BP claim (non-BP) during the observational period. METHODS: An employer claims database (1998) (1999) (2000) (2001) ) was used to identify 9009 patients (aged 18-65) diagnosed with MDD and initially treated with antidepressants (AD). A subset of patients was identified as bipolar based on a BP diagnosis claim and/or a mood stabilizer claim. Of these BP patients, unrecognized BP (UBP) patients received their initial BP diagnosis and/or mood stabilizer (MS) prescription after AD initiation, while recognized BP (RBP) patients had these records on/before AD initiation. Medical costs are total payments to providers; indirect costs are payments to employees for lost work time. RESULTS: BP patients accounted for 7.0% of the research sample (3.7% UBP, 3.3% RBP). UBP patients incurred significantly more monthly medical costs in the 12 months following initiation of AD treatment than RBP patients, for both non-BP treatment costs ($1081 versus $683) and total medical costs ($1179 versus $802). MDD total medical costs ($585) were significantly lower than both RBP and UBP costs. In the 6 months before the Index Date, UBP and RBP patient monthly costs for medical care other than BP treatment were similar ($542 versus $504, respectively). MDD total medical costs ($436) were significantly lower than RBP total costs ($631), but not UBP total costs ($542). Monthly indirect costs are significantly greater for UBP and RBP employees compared to MDD employees in the 12 months following the Index Date ($570, $514, and $335, respectively 
To compare the mental health resource use associated with risperidone, olanzapine, and quetiapine for treatment of bipolar disorder in a real-world setting.
METHODS:
This was a retrospective, comparative study based on claims data compiled from several US health plans from 1999 to early 2002. Antipsychotic treatment episodes were constructed to more accurately identify mental health resources associated with risperidone, olanzapine, and quetiapine. Selection bias was reduced by focusing only on episodes involving antipsychotic monotherapy and for which the patient did not switch from a prior antipsychotic. The primary measure analyzed was non-antipsychotic mental health care charges per patient per month (PPM), defined as total mental health care charges excluding antipsychotic drug charges during treatment episodes with risperidone, olanzapine, or quetiapine. To control for differences in patient characteristics, regression models combining risperidone, olanzapine, and quetiapine treatment episodes were estimated to determine their effects on non-antipsychotic mental health resource use. RESULTS: Regression estimates showed that quetiapine was associated with the lowest non-antipsychotic mental health care charges PPM. These charges averaged about $14 PPM (P = 0.069) and $9 PPM (P = 0.231) lower than those of risperidone and olanzapine, respectively, a savings of 2%-3% based on a $526 PPM mean charge. Differences in nonantipsychotic mental health care charges PPM among bipolar patients treated with risperidone, olanzapine, or quetiapine were largely explained by differing patient and treatment characteristics rather than the antipsychotic used. After dosage levels were standardized, however, olanzapine was associated with significantly higher drug acquisition costs than those of risperidone and quetiapine (57% and 49% respectively; P < 0.01). Although the difference in drug charges between risperidone and quetiapine was not statistically significant, quetiapine was associated with lower PPM resource utilization. CON-CLUSION: Quetiapine appears to be associated with modestly lower non-antipsychotic mental health resource use compared to risperidone and olanzapine for treatment of bipolar disorder. 
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PATTERNS OF TREATMENT AMONG BIPOLAR DISORDER PATIENTS TREATED WITH ANTIDEPRESSANTS
OBJECTIVE:
This study compared treatment patterns for bipolar disorder (BP) patients (recognized and unrecognized) to those of major depression disorder (MDD) patients without a BP claim (non-BP) during the observational period. METHODS: An employer administrative claims database (covering several managed care health plans from 1998-2001) was used to identify 11,464 patients diagnosed with MDD and initially treated with antidepressants (AD). Of these, unrecognized BP (UBP) patients received their initial BP diagnosis and/or mood stabilizer (MS) prescription after AD initiation, while recognized BP (RBP) patients had these records on/before AD initiation. Induced BP patients were defined as those manifesting mania within six months after starting AD. RESULTS: BP patients accounted for 6.8% of the research sample (3.7% UBP and 3.1% RBP). Induced BP represented 6.6% of all BP patients. RBP patients had a slightly lower rate of induction (6.2%) than UBP patients (6.9%). The use of combination therapies varied in the non-BP, UBP, and RBP patients (11%, 32%, and 43%, respectively) (all pairwise p < 0.01). The use of MS was less frequent among UBP than RBP patients (14% and 34%, respectively) (p < 0.0001). CONCLUSIONS: A substantial number of AD-treated MDD patients could be classified as bipolar (either RBP or UBP), and were at risk for induction of mania. RBP and UBP patients initiated with more combination therapies, as compared to Non-BP patients. MS use increased when BP was recognized. More effort is needed to quickly diagnose and effectively treat BP patients. . Outcome measures included days in acute care, total direct medical costs, and incremental costs. RESULTS: Because of greater tolerability, estimated days in acute care were lowest for ziprasidone (42.4) when compared to olanzapine (42.8), risperidone (43.1), or haloperidol (53.6). Due to lower estimated days in acute care and lower maintenance treatment drug costs, estimated annual total healthcare costs for each drug cohort (n = 1000 patients per cohort) were lowest for those patients initiating treatment with ziprasidone vs. risperidone (+$787,000), olanzapine (+$964,000), or haloperidol (+$4,210,000). Sensitivity analyses to changes in model assumptions for adverse event, adherence, and relapse rates, and healthcare costs were robust to these conclusions. CONCLUSION: Ziprasidone has an adverse event profile distinct from those of other atypical antipsychotics and lower pharmaceutical acquisition costs, which potentially lead to improved outcomes and lower total direct costs. 
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OLANZAPINE VERSUS RISPERIDONE IN THE
